Table 1.
Participant characteristics.
| Oral (N=32) | Transdermal (N=28) | |
|---|---|---|
| Age (years)1 | 50 ± 14 | 48 ± 9.9 |
| Menopause | ||
| Pre | 18 (56%) | 18 (64%) |
| Post | 14 (44%) | 10 (36%) |
| Race | ||
| European | 25 (78%) | 24 (86%) |
| Non- European | 7 (22%) | 4 (14%) |
| Indication for mastectomy | ||
| Invasive cancer | 13 (41%) | 17 (61%) |
| DCIS | 8 (25%) | 2 (7%) |
| Non-cancer | 11 (34%) | 9 (32%) |
| Mastectomy with Tumescence | 18 (56%) | 19 (68%) |
| Breast size (cup size) | ||
| Small (A&B) | 15 (47%) | 11 (39%) |
| Medium/Large (≥C) | 15 (47%) | 16 (57%) |
| Not available | 2 (4%) | 1 (4%) |
| BMI | ||
| Normal (<25) | 17 (53%) | 10 (36%) |
| Overweight (25–29.9) | 6 (19%) | 10 (36%) |
| Obese (≥30) | 8 (25%) | 8 (29%) |
| Not available | 1 (3%) | 0 (0%) |
| Tumor markers, clinical assays | (N=21) | (N=19) |
| ER status | ||
| Positive | 18 (86%) | 15 (79%) |
| Negative (<1%) | 3 (14%) | 2 (16%) |
| Not available | 0 (0%) | 2 (11%) |
| PR status | ||
| Positive | 15 (71%) | 14 (73%) |
| Negative (<1%) | 5 (24%) | 3 (11%) |
| Not available | 1 (5%) | 2 (11%) |
| HER-2 status | ||
| Positive | 0 (0%) | 2 (10.5%) |
| Negative | 13 (62%) | 15 (79 %) |
| Not available2 | 8 (38%) | 2 (10.5%) |
| Tumor size (cm)1 | 1.5 ± 1.1 | 2.2 ± 1.7 |
1
Age and tumor size are reported as mean ± SD. Tumor size was not available for one subject in transdermal group (N=18).
2
HER-2 status was not available for DCIS cases.